The content on this site is intended for healthcare professionals only
Exposure to histone deacetylase (HDAC) inhibitors sensitise triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin, according to preclinical research presented at the 35th San Antonio Breast Cancer Symposium.
Dr Kapil Bhalla explains how HDAC inhibition indirectly causes DNA damage and impairs the cells ability to repair damaged DNA. These effects mimic those in BRCA1 mutated breast cancer cells and cause cells to become more susceptible to PARP inhibitor and cisplatin therapy.
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Addressing the rise of multiple myeloma in Rwanda
ASCO 2024: Lung cancer highlights
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert round up July 28th to August 3rd, 2023
Updates on HR-positive HER2-negative breast cancer
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
